PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methenamine Hippurate→

Methenamine Hippurate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
5714-73-8
Molecular formula
C15H21N5O3
Molecular weight
319.36 g/mol
Drug class
Urinary antisepticmethenamine salt of hippuric acid
Mechanism of action
In acidic urine, methenamine is hydrolysed to formaldehyde, which exerts nonspecific antibacterial activity within the urinary tract. Hippuric acid contributes urinary acidification; effectiveness depends on maintaining sufficiently acidic urine.
Indications / reported uses
  • Prophylaxis or suppressive treatment of recurrent urinary-tract infections after the active infection has been eradicated by appropriate antibacterial therapy; not for treatment of acute pyelonephritis or systemic infection

Sources: US DailyMed — Methenamine hippurate tablets, label updated 21 May 2026 · NLM MeSH — Methenamine hippurate · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Methenamine Hippurate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methenamine Hippurate Permitted Daily Exposure (PDE) report (the Methenamine Hippurate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methenamine Hippurate Occupational Exposure Limit (OEL) report (the Methenamine Hippurate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.